GSK reported October 28 that third-quarter sales rose 4% at actual exchange rates to £8.887 billion, while total operating profit fell 18% to £2.127 billion.
The drugmaker attributed the earnings decline to £328 million in major restructuring charges linked to its Accelerate Growth program and lower other net operating income, partly offset by higher core operating profit.
On GSK’s core measure, operating profit increased 3% at actual exchange rates to £3.076 billion. Core earnings per share fell 1% to 54.6 pence; total earnings per share declined 23% to 38.5 pence.
Sales grew 5% at constant exchange rates. Specialty medicines generated £3.9 billion, with 15% constant-currency growth. Vaccines sales fell 2% on that basis to £2.6 billion.
GSK retained its 2026 constant-currency growth forecasts of 3%–5% for turnover and 7%–9% for core operating profit and core earnings per share. The company declared a quarterly dividend of 17 pence per share.
Source: GSK, Third-Quarter 2026 Results, October 28.